BR0008963A - Epìtopos ou mimótopos derivados do domìnio dec-epsilon-2 de ige, antagonistas destes, e seususos terapêuticos - Google Patents

Epìtopos ou mimótopos derivados do domìnio dec-epsilon-2 de ige, antagonistas destes, e seususos terapêuticos

Info

Publication number
BR0008963A
BR0008963A BR0008963-0A BR0008963A BR0008963A BR 0008963 A BR0008963 A BR 0008963A BR 0008963 A BR0008963 A BR 0008963A BR 0008963 A BR0008963 A BR 0008963A
Authority
BR
Brazil
Prior art keywords
ige
domain
epsilon
epitopes
antagonists
Prior art date
Application number
BR0008963-0A
Other languages
English (en)
Inventor
Michael Dyson
Martin Friede
Judith Greenwood
Ellen Hewitt
Lan Lamont
Sean Mason
Roger Randall
William Gordon Turnell
Arcelle Paulette Van Mechelen
Carlota Vinals Y De Bassols
Original Assignee
Smithkline Beecham Biolog
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9904405.9A external-priority patent/GB9904405D0/en
Priority claimed from GBGB9907151.6A external-priority patent/GB9907151D0/en
Priority claimed from GBGB9910537.1A external-priority patent/GB9910537D0/en
Priority claimed from GBGB9910538.9A external-priority patent/GB9910538D0/en
Priority claimed from GBGB9918603.3A external-priority patent/GB9918603D0/en
Priority claimed from GBGB9918594.4A external-priority patent/GB9918594D0/en
Priority claimed from GBGB9921047.8A external-priority patent/GB9921047D0/en
Priority claimed from GBGB9921046.0A external-priority patent/GB9921046D0/en
Priority claimed from GBGB9925619.0A external-priority patent/GB9925619D0/en
Priority claimed from GBGB9927698.2A external-priority patent/GB9927698D0/en
Application filed by Smithkline Beecham Biolog, Peptide Therapeutics Ltd filed Critical Smithkline Beecham Biolog
Publication of BR0008963A publication Critical patent/BR0008963A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Abstract

Patente de Invenção: "EPìTOPOS OU MIMóTOPOSDERIVADOS DO DOMìNIO DE C-EPSILON-2 DE IGE,ANTAGONISTAS DESTES, E SEUS USOS TERAPêUTICOS". Apresente invenção refere-se à provisão de novos medicamentospara o tratamento, prevenção ou melhora de doença alérgica. Emparticular, os novos medicamentos são peptídeos isoladosincorporando os epítopos ou mimótopos de regiões expostas nasuperfície do domínio C<sym>2 de IgE. Os inventores constataramque estas novas regiões podem ser o alvo para igualmenteimunoterapia ou imunoprofilaxia passiva e ativa. A invenção aindarefere-se a métodos para a produção dos medicamentos,composições farmacêuticas contendo-os e seu uso em medicina.Também formando um aspecto da presente invenção estão osligandos, especialmente anticorpos monoclonais, que são capazesde ligarem-se às regiões de IgE expostos na superfície da presenteinvenção, e seu uso em medicina como imunoterapia passiva ouem imunoprofilaxia.
BR0008963-0A 1999-02-25 2000-02-22 Epìtopos ou mimótopos derivados do domìnio dec-epsilon-2 de ige, antagonistas destes, e seususos terapêuticos BR0008963A (pt)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GBGB9904405.9A GB9904405D0 (en) 1999-02-25 1999-02-25 Vaccine
GBGB9907151.6A GB9907151D0 (en) 1999-03-29 1999-03-29 Therapeutic antibody composition and use
GBGB9910537.1A GB9910537D0 (en) 1999-05-07 1999-05-07 Therapeutic antibody, Immunogenic compositions and uses
GBGB9910538.9A GB9910538D0 (en) 1999-05-07 1999-05-07 Therapeutic antibody, Immunogenic compositions ansd uses
GBGB9918603.3A GB9918603D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918594.4A GB9918594D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9921047.8A GB9921047D0 (en) 1999-09-07 1999-09-07 Therapeutic antibody, immunogenic compositions & uses
GBGB9921046.0A GB9921046D0 (en) 1999-09-07 1999-09-07 Therapeutic antibody composition & use
GBGB9925619.0A GB9925619D0 (en) 1999-10-29 1999-10-29 Vaccine
GBGB9927698.2A GB9927698D0 (en) 1999-11-23 1999-11-23 Therapeutic antibody
PCT/EP2000/001455 WO2000050460A1 (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses

Publications (1)

Publication Number Publication Date
BR0008963A true BR0008963A (pt) 2001-11-27

Family

ID=27579426

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008963-0A BR0008963A (pt) 1999-02-25 2000-02-22 Epìtopos ou mimótopos derivados do domìnio dec-epsilon-2 de ige, antagonistas destes, e seususos terapêuticos

Country Status (19)

Country Link
EP (1) EP1155037A1 (pt)
JP (1) JP2004538238A (pt)
KR (1) KR20020007313A (pt)
CN (1) CN1348466A (pt)
AR (1) AR029336A1 (pt)
AU (1) AU2672700A (pt)
BR (1) BR0008963A (pt)
CA (1) CA2363637A1 (pt)
CO (1) CO5210906A1 (pt)
CZ (1) CZ20013082A3 (pt)
HK (1) HK1044004A1 (pt)
HU (1) HUP0200049A2 (pt)
IL (1) IL145024A0 (pt)
MX (1) MXPA01008613A (pt)
NO (1) NO20014130L (pt)
NZ (1) NZ513679A (pt)
PL (1) PL350993A1 (pt)
TR (1) TR200102506T2 (pt)
WO (1) WO2000050460A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913327D0 (en) * 1999-06-08 1999-08-11 Smithkline Beecham Biolog Vaccine
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
AU2002254683C1 (en) * 2001-04-18 2009-01-22 Dyax Corp. Binding molecules for Fc-region polypeptides
GB0209878D0 (en) * 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
WO2008099188A1 (en) * 2007-02-15 2008-08-21 Astrazeneca Ab Binding members for ige molecules
ES2615881T3 (es) 2009-05-07 2017-06-08 Stallergenes Uso de inmunoglobulinas igg1 y/o de ligandos del receptor cd32 para el tratamiento de enfermedades y manifestaciones inflamatorias por vía mucosa.
WO2020059832A1 (ja) * 2018-09-21 2020-03-26 国立研究開発法人理化学研究所 ＩｇＥ抗体産生Ｂ細胞の膜結合型ＩｇＥ抗体に特異的に結合する抗ＩｇＥ抗体とこれを用いたアレルギー症状の診断および治療方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4171299A (en) * 1975-04-04 1979-10-16 The Regents Of The University Of California Polypeptide agents for blocking the human allergic response
AU6532498A (en) * 1996-12-06 1998-06-29 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Inhibition of ige-mediated allergies by a human ige-derived oligopeptide
EP0996857B1 (en) * 1997-07-17 2009-09-09 Ludwig Institute For Cancer Research Cancer associated nucleic acids and polypeptides

Also Published As

Publication number Publication date
NO20014130L (no) 2001-09-13
HK1044004A1 (zh) 2002-10-04
CN1348466A (zh) 2002-05-08
NZ513679A (en) 2001-09-28
IL145024A0 (en) 2002-06-30
KR20020007313A (ko) 2002-01-26
PL350993A1 (en) 2003-02-24
CZ20013082A3 (cs) 2002-02-13
AR029336A1 (es) 2003-06-25
EP1155037A1 (en) 2001-11-21
HUP0200049A2 (en) 2002-05-29
NO20014130D0 (no) 2001-08-24
WO2000050460A1 (en) 2000-08-31
CO5210906A1 (es) 2002-10-30
AU2672700A (en) 2000-09-14
JP2004538238A (ja) 2004-12-24
MXPA01008613A (es) 2003-06-24
TR200102506T2 (tr) 2002-06-21
CA2363637A1 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
Dai et al. Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy
DE69931377T2 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
Leanza et al. Pharmacological targeting of ion channels for cancer therapy: in vivo evidences
Mandal et al. Targeting CDK9 for anti-cancer therapeutics
NO20014131L (no) Epitoper eller mimotoper avledet fra C-epsilon-3- eller C- epsilon-4-domener fra IgE, antagonister derav og deresterapeutiske anvendelser
Thangam et al. Induction of ROS-dependent mitochondria-mediated intrinsic apoptosis in MDA-MB-231 cells by glycoprotein from Codium decorticatum
UY28170A1 (es) Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
Hadigal et al. Exploiting herpes simplex virus entry for novel therapeutics
Das et al. Promise of the NLRP3 inflammasome inhibitors in in vivo disease models
BR0008963A (pt) Epìtopos ou mimótopos derivados do domìnio dec-epsilon-2 de ige, antagonistas destes, e seususos terapêuticos
Dong et al. Targeting the interplay of autophagy and ROS for cancer therapy: An updated overview on phytochemicals
Maurya et al. Dark classics in chemical neuroscience: an evidence-based systematic review of belladonna
ES2908141T3 (es) Formulaciones y dosis de cannabinoides
Bharate et al. Discovery and preclinical development of IIIM-160, a Bergenia ciliata-based anti-inflammatory and anti-arthritic botanical drug candidate
RU2019113989A (ru) Лекарственное средство
Silva et al. The quassinoid isobrucein B reduces inflammatory hyperalgesia and cytokine production by post-transcriptional modulation
BR0008964A (pt) Epìtopos ou mimótopos derivados dos campos dec-epsilon-3 ou c-epsilon-4 de ige, antagonistas dosmesmos e seus usos terapêuticos
WO2002034288A3 (en) Vaccine for treating allergy
Szuster-Ciesielska et al. Immunogenic Evaluation of Ribosomal P-Protein Antigen P0, P1, and P2 and Pentameric Protein Complex P0-(P1-P2) 2 of Plasmodium falciparum in a Mouse Model
Ushkalova et al. Sodium Metamizole: Regulatory Status around the World, Safety Problems and Medication Errors
Bussing et al. Pharmacokinetics of monoclonal antibody and antibody fragments in the mouse eye following systemic administration
Karam et al. New approach for improving production of Naja haje snake antivenom
EA199900438A1 (ru) Препарат местного применения для введения пептидных лекарственных средств в живые организмы
ZA200709069B (en) Pharmaceutical Formulation for treatment of acquired immune deficiency syndrome (AIDS). Obtaining procedure
JP2013512279A (ja) ＩｇＥ媒介性疾患の処置方法

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1929 DE 26/12/2007.